enGene (NASDAQ:ENGN) Now Covered by Wells Fargo & Company

Analysts at Wells Fargo & Company initiated coverage on shares of enGene (NASDAQ:ENGN) in a report issued on Monday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $30.00 price target on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 96.59% from the company’s previous close.

A number of other research firms have also commented on ENGN. Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Morgan Stanley began coverage on enGene in a research note on Friday, March 8th. They issued an “overweight” rating and a $40.00 price objective on the stock. Guggenheim began coverage on enGene in a research note on Monday, April 15th. They issued a “buy” rating and a $34.00 price objective on the stock. SVB Leerink began coverage on enGene in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price objective on the stock. Finally, UBS Group assumed coverage on enGene in a research note on Thursday, March 28th. They issued a “buy” rating and a $37.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $34.40.

enGene Trading Up 3.1 %

enGene stock opened at $15.26 on Monday. The business has a 50 day moving average of $16.27. enGene has a one year low of $6.69 and a one year high of $43.00.

Insider Transactions at enGene

In other news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares of the company’s stock, valued at $45,542,295. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Hedge Funds Weigh In On enGene

A number of institutional investors have recently modified their holdings of ENGN. Fcpm Iii Services B.V. acquired a new position in shares of enGene during the fourth quarter worth approximately $80,097,000. BVF Inc. IL bought a new stake in enGene during the fourth quarter worth $20,777,000. Omega Fund Management LLC bought a new stake in enGene during the fourth quarter worth $10,441,000. Finally, Vivo Capital LLC bought a new stake in enGene during the fourth quarter worth $6,264,000. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.